Clinical Trial Update: A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study evaluating brentuximab vedotin in combination with multi-agent chemotherapy for Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Disease, Hodgkin | Phase 1 | Status: COMPLETED